Korro Bio, Inc. Recapitalization Costs
Korro Bio, Inc. (KRRO) reported Recapitalization Costs of $12.25 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RecapitalizationCosts · last filed 2025-03-18
- Korro Bio, Inc. recapitalization costs for fiscal 2023 was $12.25M.
| Period end | Recapitalization Costs 12 month |
|---|---|
| 2023-12-31 | $12.25M 10-K · filed 2025-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |